Strides Pharma Science Limited has informed the Exchange about press release dated 14-Nov-2022 titled Stelis receives a positive recommendation from European Medicines Agency (EMA) granting market authorization for KaulivTM, a recombinant human teriparatide biosimilar to treat osteoporosis.
Press Release Nov 14 2022
Filed with NSE · · 3 pages · English
Release
Strides Pharma Science Ltd on 6ix
Earlier from Strides Pharma Science
- Share Warrants
- Press Release Sep 01 2022
- Press Release Aug 26 2022
- Press Release Aug 18 2022
- Press Release Aug 08 2022
Later from Strides Pharma Science
- Press Release Nov 18 2022
- Press Release Dec 22 2022
- Press Release Dec 28 2022
- Strides Pharma Science Ltd Press Release Jan 18 2023
- Press Release Jan 20 2023
Follow Strides Pharma Science into a list and get an email when it puts out news.
Follow Strides Pharma Science